Boost

The vendor opportunity at Boost

Boost is a health-services franchise with 3 franchised locations. The brand’s unit count declined by 50% year-over-year, signaling a period of contraction or consolidation. For software vendors, this means the immediate addressable market is small—just 3 units—but the mandated technology stack creates a captive audience. Every location must run an EMR, an accounting system, and patient management software. If you sell into one unit, you effectively sell into all, provided you win HQ approval.

The royalty rate is 5.0%. Average unit volume (AUV) is not disclosed in the 2026 FDD. The initial term length is also not disclosed. These gaps make it harder to model ROI for the franchisee, but the HQ mandate means the franchisor controls the software conversation entirely.

Who controls software purchasing

All software purchasing decisions flow through Boost’s headquarters. The FDD lists five executives in Item 1: J.J. Sorrenti (Chief Executive Officer), Kevin Vesely (Chief Financial Officer), Jennifer LoBianco (Chief Marketing Officer), Rebecca Bouchard (Brand President), and Jake Baker (Clinical and Compliance Director). For a vendor pitch, the most direct paths are through the CEO and CFO, who hold budgetary authority. The Clinical and Compliance Director is likely the gatekeeper for EMR and patient management tools, given the regulatory sensitivity of health-services data.

There are no multi-unit operators mapped in our corpus, so no franchisee-level buying centers exist outside HQ. This is a pure top-down sales environment.

Mandated and current tech stack

Boost’s FDD mandates three categories of technology: an accounting system, an EMR, and patient management software. The specific vendors are not named in the FDD, which means the brand either leaves vendor selection to HQ discretion within a compliance framework or has not disclosed its preferred partners. Vendors approaching Boost should come prepared to demonstrate HIPAA compliance, interoperability with common health-tech APIs, and a track record in small clinical networks.

Because the brand operates in health services, any software that touches patient data must meet federal and state privacy standards. This is a non-negotiable threshold.

Procurement, renewals, and timing

The FDD does not include an Item 8 extract, so we cannot confirm whether Boost designates specific suppliers or maintains an approved-vendor program. Similarly, Item 17 renewal signals are absent, and the initial term length is not disclosed. This lack of transparency makes it difficult to predict contract cycles. With only 3 units and a shrinking footprint, procurement events may be ad hoc rather than calendar-driven.

Vendors should monitor any public announcements from Boost’s leadership team for signals of operational restructuring or technology refreshes. A direct outreach to the CFO or Clinical Director, framed around compliance and cost efficiency, is the most practical entry point.

How to read the Boost FDD

The Boost Franchise Disclosure Document is embedded below. It was filed with state franchise regulators in 2026. Key sections for software vendors include Item 1 (executives), Item 11 (mandated systems), and Item 8 (procurement restrictions, if present). Because several items are not extracted in our data, the full PDF is essential for due diligence. Review it to confirm whether any vendor names appear in the mandated tech list and to check for any undisclosed renewal or purchasing terms.

For a ranked list of franchise targets matched to your software category, FranCloud can help.